Publications by authors named "Gary P Frenette"
Article Synopsis
- - The study investigated the effects of the AKT inhibitor MK-2206 on patients with recurrent/metastatic adenoid cystic carcinoma (ACC), a rare and incurable cancer, aiming to reduce MYB expression and induce tumor regression.
- - Sixteen patients were treated but there were no confirmed responses; however, 13 maintained stable disease, with a median progression-free survival of 9.7 months and overall survival of 18 months.
- - While MK-2206 did decrease MYB levels in some patients, its clinical efficacy was limited, suggesting a need for new strategies to target MYB in ACC.
